Thiamine-Responsive Megaloblastic Anemia Syndrome Combined with Thalassemia Trait: A Rare Association

Abstract

Introduction Thiamine-responsive megaloblastic anemia syndrome (TRMA, OMIM reference 249270), also known as Rogers' syndrome, is a rare type of anemia characterized by the triad megaloblastic anemia, sensorineural hearing loss, and diabetes mellitus (DM). Disturbance of thiamine transport into cells results from homozygous or compound heterozygous mutations in the SLC19A2 gene.

Case Report We report the case of an 8-year-old girl who presented at age 4 years with anemia. She had a combined hematological profile of microcytic and macrocytic anemia. The parents refused bone marrow aspiration and genetic diagnosis. Hemoglobin electrophoresis established the thalassemia trait. She was later confirmed to have sensorineural deafness and monogenic DM. A tentative TRMA diagnosis was based on megaloblastic anemia, sensorineural deafness, and monogenic DM triad. The patient was treated empirically with a daily dose of thiamine 200 mg; her hemoglobin level normalized, but the deafness and DM did not improve.

Conclusion In routine practice, patients with TRMA must be evaluated thoroughly for other causes of megaloblastic anemia, including therapeutic thiamine trials in the presence of sensorineural deafness or DM. These patients should be followed throughout their life span both for DM and to control their response to thiamine therapy for megaloblastic anemia.

Keywords

monogenic diabetes mellitus - sensorineural deafness - megaloblastic anemia - vitamin B1 deficiency - thalassemia trait

Author Contributions

The authors contributed equally to the study.

Compliance with Ethical Principles

No prior ethical approval is required for single case reports.

Declaration of Patient Consent

Appropriate consent was obtained.

Publikationsverlauf

Artikel online veröffentlicht:
28. August 2023

• References

• 1 Porter FS, Rogers LE, Sidbury Jr JB. Thiamine-responsive megaloblastic anemia. J Pediatr 1969; 74 (04) 494-504
• 2 Spehar Uroic A, Milenkovic D, De Franco E, Bilic E, Rojnic Putarek N, Krnic N. Importance of immediate thiamine therapy in children with suspected thiamine-responsive megaloblastic anemia-report on two patients carrying a novel SLC19A2 gene mutation. J Pediatr Genet 2020; 11 (03) 236-239
• 3 Sanyoura M, Philipson LH, Naylor R. Monogenic diabetes in children and adolescents: recognition and treatment options. Curr Diab Rep 2018; 18 (08) 58
• 4 Amr K, Pawlikowska P, Aoufouchi S, Rosselli F, El-Kamah G. Whole exome sequencing identifies a new mutation in the SLC19A2 gene leading to thiamine-responsive megaloblastic anemia in an Egyptian family. Mol Genet Genomic Med 2019; 7 (07) e00777
• 5 Beshlawi I, Al Zadjali S, Bashir W, Elshinawy M, Alrawas A, Wali Y. Thiamine responsive megaloblastic anemia: the puzzling phenotype. Pediatr Blood Cancer 2014; 61 (03) 528-531
• 6 Shaw-Smith C, Flanagan SE, Patch A-M. et al. Recessive SLC19A2 mutations are a cause of neonatal diabetes mellitus in thiamine-responsive megaloblastic anaemia. Pediatr Diabetes 2012; 13 (04) 314-321
• 7 Lagarde WH, Underwood LE, Moats-Staats BM, Calikoglu AS. Novel mutation in the SLC19A2 gene in an African-American female with thiamine-responsive megaloblastic anemia syndrome. Am J Med Genet A 2004; 125A [phone]
• 8 Manimaran P, Subramanian VS, Karthi S. et al. Novel nonsense mutation (p.Ile411Metfs*12) in the SLC19A2 gene causing thiamine responsive megaloblastic anemia in an Indian patient. Clin Chim Acta 2016; 452: 44-49
• 9 Alzahrani AS, Baitei E, Zou M, Shi Y. Thiamine transporter mutation: an example of monogenic diabetes mellitus. Eur J Endocrinol 2006; 155 (06) 787-792
• 10 Onal H, Bariş S, Ozdil M. et al. Thiamine-responsive megaloblastic anemia: early diagnosis may be effective in preventing deafness. Turk J Pediatr 2009; 51 (03) 301-304